Pilot study of denosumab in BRCA1/2 mutation carriers scheduled for risk-reducing salpingo-oophorectomy (DENOSUMAB)
Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy (Removal of Fallopian Tube and Ovary)
Sponsor: National Cancer Institute
Enrolling: Female Patients Only
IRB Number: AAAR6281
U.S. Govt. ID: NCT03382574
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine if denosumab treatment affects the rate of growth of the cells in the ends of the fallopian tubes compared to receiving no treatment in premenopausal BRCA1/2 mutation carriers.
This study is closed
Investigator
Meghna Trivedi, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have a BRCA 1 or BRCA 2 mutation? Yes No
Are you pre-menopausal? Yes No
Are you planning to have surgery to remove your ovaries and fallopian tubes? Yes No
Are you willing to take oral calcium and vitamin D? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE